Redeye is positive about SciBase’s first positive coverage decision from a private US insurer, Highmark Blue Cross Blue Shield, which serves more than 7 million members across several states. We view the decision as a key milestone for the company, as reimbursement is one of the most important factors for accelerating the adoption of Nevisense in the US. The news strengthens our positive view of SciBase and increases our confidence in our estimates going forward.
LÄS MER
